Outcomes of Patients With High-Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG-I Study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.

The BIOMAG-I study, with comprehensive OCT and IVUS imaging, offers a unique opportunity to investigate high-risk plaque morphology and its vascular response.

Why It Was Studied

Early identification and targeted treatment of coronary lesions at higher risk of future events remains a major unmet need in coronary artery disease research.

Invasive treatment of such plaques is controversial.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

This post-hoc analysis included patients with stable coronary artery disease and high-quality intravascular imaging.

How the Study Was Run

Subgroups were further stratified by the presence of MLA < 4 mm², TCFA < 80 μm, lipid arc >90°, or all combined PB was assessed by IVUS or estimated by OCT when IVUS was unavailable.

LLL was measured at 6 and 12 months.

What Was Measured

PubMed files the paper under topics including Absorbable Implants, Coronary Angiography, Coronary Artery Disease, Coronary Vessels, Magnesium, Percutaneous Coronary Intervention and Plaque, Atherosclerotic.

Author keywords: bioresorbable scaffold, high risk lesions, intravascular imaging, intravascular ultrasound, late lumen loss and optical coherence tomography.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.